Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bumetanide in heart failure in infancy.

O C Ward, L K Lam

    Archives of Disease in Childhood
    |November 1, 1977
    PubMed
    Summary

    Bumetanide effectively reduced fluid overload in infants with congenital heart disease and cardiac failure. This diuretic showed significant natriuresis and chloruresis with no observed side effects in short-term and long-term studies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Irish contribution to the eradication of rheumatic fever.

    Irish medical journal·2010
    Same author

    Victorian medical politics: the fate of Dr Alfred Stephens (1821-90).

    Journal of medical biography·2010
    Same author

    Photorefractive-index gratings formed by nanosecond optical pulses in BaTiO(3).

    Optics letters·2009
    Same author

    Generation of a time-reversed replica of a nonuniformly polarized image-bearing optical beam.

    Optics letters·2009
    Same author

    Lymphadenopathy of IgG4-related sclerosing disease.

    The American journal of surgical pathology·2008
    Same author

    The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.

    Clinical and experimental dermatology·2005

    Area of Science:

    • Pediatrics
    • Cardiology
    • Pharmacology

    Background:

    • Congenital heart disease (CHD) frequently leads to cardiac failure in infants.
    • Diuretic therapy is essential for managing fluid overload in these patients.

    Purpose of the Study:

    • To evaluate the efficacy and safety of bumetanide in infants with CHD and cardiac failure.
    • To assess bumetanide's effects in both acute and long-term treatment settings.

    Main Methods:

    • A study involving 12 male infants for acute (3-day) assessment and 13 infants for long-term (mean 10.5 weeks) evaluation.
    • Administration of bumetanide at varying doses, starting from 0.015 mg/kg.
    • Monitoring for diuretic effects (natriuresis, chloruresis) and adverse events.

    Main Results:

    • Even a suboptimal dose (0.015 mg/kg) in the acute phase induced significant natriuresis and chloruresis.
    • Bumetanide proved effective as a long-term diuretic in doses ranging from 0.015 mg/kg every other day to 0.10 mg/kg daily.
    • No adverse side effects were reported during either the acute or long-term treatment periods.

    Conclusions:

    • Bumetanide is a safe and effective diuretic for managing cardiac failure in infants with congenital heart disease.
    • The drug demonstrates efficacy in both short-term and extended treatment durations.
    • Further research may explore optimal dosing strategies for bumetanide in this pediatric population.

    Related Experiment Videos